


Supplementary Figures:



Supplementary Figure S1: Outcome of AMKL patients treated with allogeneic HSCT in CR1 or to chemotherapy only for the AML-BFM 98 or AML-BFM 04 study. (A) Event-free survival in AML-BFM 98. (B) Overall survival in AML-BFM 98. (C) Event-free survival in AML-BFM 04. (D) Overall survival in AML-BFM 04. Patients without SCT and EFS below the median time to transplantation (0.4 years) were excluded. 5-year probabilities are given.